On the other hand, a clinical trial using the concept of preclinical AD with standard thresholds ([18F]florbetapir SUVR >1.15 and p-tau >23 pg/ml) would require 416 individuals per arm, whereas a trial without a population enrichment strategy would require 738 individuals per arm. The gene discussed is MAPT; the disease is Alzheimer disease.